BriaCell Therapeutics - Warrants (24/02/2025) Accounts Payable

As of the most recent data (April 2026), BCTXW shows a accounts payable of $2.2M. That compares with $3.3M in the prior-year period — down 33.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCTXW's accounts payable is now $2.2M (was $3.3M) — a 33.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BriaCell Therapeutics - Warrants (24/02/2025) is outperforming or lagging.

Tracking BCTXW's accounts payable over time shows whether BriaCell Therapeutics - Warrants (24/02/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $2.2M That compares with $3.3M in the prior-year period — down 33.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has BriaCell Therapeutics - Warrants (24/02/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.2M) with ownership activity and broader fundamentals.

BriaCell Therapeutics - Warrants (24/02/2025)'s accounts payable is $2.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.